SBIR-STTR Award

Clinical validation of a/LCI for detecting pre-cancerous lesions in the esophagus
Award last edited on: 10/7/19

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$4,054,561
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Steven C Gebhart

Company Information

Oncoscope Inc

318 Blackwell Street Suite 240
Durham, NC 27701
   (919) 251-8030
   info@oncoscope.com
   www.oncoscope.com
Location: Single
Congr. District: 04
County: Durham

Phase I

Contract Number: 1R43CA128163-01A1
Start Date: 3/1/07    Completed: 7/31/11
Phase I year
2007
Phase I Amount
$133,874
The objective of this research is to create a commercial prototype of a new optical biopsy system based on angle-resolved Low Coherence Interferometry (a/LIC). A/LCI is a novel optical technique that uses interferometric detection of elastically scattered light to probe the nuclear morphology of esophageal epithelium. The ability of a/LCI to obtain quantitative measurements of cellular characteristics, such as nuclear size and optical density, without the need for either exogenous stains or fixatives, makes it an excellent candidate to become a screening tool for in vivo detection of pre-cancerous tissue states such as intraepithelial neoplasia. As its name implies, a/LCI detects the angular distribution of scattered light using a low-coherence interferometer. The technique enables selective detection of the optical field scattered from a small region within probed tissue by exploiting the coherence properties of broadband light. The ability to probe sub-surface cellular morphology is especially important for detecting pre- cancerous changes in epithelial tissues, where changes in the basal cell layer, approximately 100 5m beneath the surface are the most important diagnostic of tissue health. The long-range goal of this research is to create a new a/LCI-based biomedical diagnostic product for the purpose of endoscopically identifying and monitoring neoplastic transformations in humans. The research plan, proposed here, will create a prototype which can be applied in clinical studies to evaluate the feasibility of using a/LCI for tissue screening and surveillance by achieving the following milestones: (1) constructing a new a/LCI system prototype capable of rapid data acquisition through a coherent fiber bundle, (2) advancing the prototype design by implementing a novel fiber probe geometry suitable for application during endoscopic procedures, and (3) testing the functionality of the new prototype by examining ex vivo tissue sample from a rat model for esophageal cancer.The objective of this research is to develop a new instrument for detecting early stage cancer in human epithelial tissues based on a novel optical spectroscopic technique, The proposed a/LCI instrument will serve as a guide to biopsy for clinicians, enabling evaluation of tissue health in situ, prior to tissue removal. This technique has the potential to greatly improve upon the current method of random biopsy for screening for and surveillance of early stage epithelial cancers

Phase II

Contract Number: 2R44CA128163-02
Start Date: 3/1/07    Completed: 7/31/11
Phase II year
2009
(last award dollars: 2013)
Phase II Amount
$3,920,687

The objective of this research is to create a clinical prototype of a new optical biopsy system based on angle-resolved low coherence interferometry (a/LCI). a/LCI is a novel optical technique that uses interferometric detection of elastically scattered light to probe the nuclear morphology of esophageal epithelium. The ability of a/LCI to obtain quantitative measurements of cellular characteristics, such as nuclear size and optical density, without the need for either exogenous stains or fixatives, makes it an excellent candidate to become a screening tool for in vivo detection of pre-cancerous tissue states such as intraepithelial neoplasia. As its name implies, a/LCI detects the angular distribution of scattered light using a low-coherence interferometer. The technique enables selective detection of the optical field scattered from a small region within probed tissue by exploiting the coherence properties of broadband light. The ability to probe sub-surface cellular morphology is especially important for detecting pre- cancerous changes in epithelial tissues, where changes in the basal cell layer, approximately 100 5m beneath the surface are the most important diagnostic of tissue health. The long-range goal of this research is to create a new a/LCI-based biomedical diagnostic product for the purpose of endoscopically identifying and monitoring neoplastic transformations in humans. The research plan will create and test a clinically viable a/LCI system by achieving the following milestones: (1) conducting multi-site human clinical trials to quantitatively assess clinical utility of a/LCI for surveillance and treatment monitoring of esophageal dysplasia, (2) continuing the innovation of the Phase I hardware and probe design to optimize clinical utility of the a/LCI system and (3) developing software for tissue diagnosis based on a/LCI imaging.

Public Health Relevance:
The objective of this research is to develop a new instrument for detecting early stage cancer in human epithelial tissues based on a novel optical spectroscopic technique, angle-resolved low coherence interferometry (a/LCI). The proposed a/LCI instrument will serve as a guide to biopsy and treatment monitoring for clinicians, enabling evaluation of tissue health in situ, prior to tissue removal. This technique has the potential to greatly improve upon the current method of random biopsy for screening and surveillance of early stage epithelial cancers.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.